Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face

References

• Stanley MA. Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002; 27: 571–7
   PubMed Web of Science ®Google Scholar
• Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifier, R-848 and imiquimod. Cell Immunol. 1999; 191: 10–9
   PubMed Web of Science ®Google Scholar
• Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000; 114: 135–41
   PubMed Web of Science ®Google Scholar
• Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifier imiquimod and R-848 are potent activators of B lymphocytes. . Cell Immunol. 2000; 203: 55–65
   PubMed Web of Science ®Google Scholar
• Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators progress toward treating inflammation, infection and cancer. Lancet Infect Dis. 2001; 1: 189–98
   PubMedGoogle Scholar
• Smith KJ, Hamza S, Skelton H. The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin Pharmacother. 2003; 4: 1105–19
   PubMed Web of Science ®Google Scholar
• Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005; 31: 318–23
   PubMed Web of Science ®Google Scholar
• Eklind J, Tartler U, Maschke J, Lidbrink P, Hengge UR. Imiquimod to treat different cancers of the epidermis. Dermatol Surg. 2003; 29: 890–6, discussion 896
   PubMed Web of Science ®Google Scholar
• Paternò EJ, Campione E, Diluvio L, Orlandi A, Chimenti S. Imiquimod for restoring local immunità in a renal transplant patient affected by persistent keratoacanthoma. Dermatol Online J. 2008; 14: 8
   PubMedGoogle Scholar
• Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004; 151: 485–8
   PubMed Web of Science ®Google Scholar
• Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005; 52: 715–16
   PubMed Web of Science ®Google Scholar
• Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 104: 1490–5
   Google Scholar
• Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol. 2005; 141: 908–9
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Petrillo G, Argenziano G. Aphthous ulcers and imiquimod. J Am Acad Dermatol. 2005; 53: 360–1
   PubMed Web of Science ®Google Scholar
• Barton JC. Angioedema associated with imiquimod. J Am Acad Dermatol. 2005; 51: 477–8
   Web of Science ®Google Scholar
• Stinco G, Frattasio A, Forcione M, Quinkenstein E, Finato N, Patrone P. The appearance of inflammatory papules in the skin surronding areas treated with imiquimod cream for basal cell carcinoma. Br J Dermatol. 2008; 158: 408–9
   PubMed Web of Science ®Google Scholar
• Marty CL, Randle HW, Walsh JS. Eruptive EC resulting from treatment with imiquimod. Dermatol Surg. 2005; 31: 780–3
   PubMed Web of Science ®Google Scholar
• Nasca MR, Micali G. Multiple and clustered eruptive EC following treatment with topical imiquimod. Dermatology. 2007; 215: 352–3
   PubMed Web of Science ®Google Scholar
• Mcgibbon DH, Mckee PH. Tumors of the epidermal appendages. Pathology of the skin. JB Lippincot, Philadelphia 1989; 13: 3
   Google Scholar
• Dini M, Innocenti A, Romano F. Basal cell carcinoma arising from epidermoid cyst: A case report. Dermatol Surg. 2001; 27: 585–6
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003; 85: 85–95
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004; 303: 1526–9
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subset of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001; 194: 863–9
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499–511
   PubMed Web of Science ®Google Scholar
• Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res. 1994; 14: 81–5
   PubMedGoogle Scholar
• Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992; 52: 3528–33
   PubMed Web of Science ®Google Scholar
• Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007; 204: 1441–51
   PubMed Web of Science ®Google Scholar
• Menzies SW, Westerhoff K, Rabinovits H, Kopf AW, Mccarthy WH, Katz B. Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol. 2000; 136: 1012–16
   PubMed Web of Science ®Google Scholar
• Smith SP, Konnikov N. Eruptive epidermal cysts and multiple squamous cell carcinomas after therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1991; 25: 940–3
   PubMed Web of Science ®Google Scholar
• Ghaffar SA, Clements SE, Lear JT. EC mimicking recurrence of superficial basal cell carcinoma following photodynamic therapy. Clin Exp Dermatol. 2007; 32: 223–4
   PubMed Web of Science ®Google Scholar
• Kurokawa I, Umeda K, Nishimura K, Yamanaka KI, Hakamada A, Isoda KI, et al. Br J. Dermatol. 2007; 157: 388–431
   Google Scholar
• Barland CO, Zettersten E, Brown BS, Ye J, Elias PM, Ghadially R. Imiquimod-induced interleukin-1α stimulation improves barrier homeostasis in aged murine epidermidis. J Invest Dermatol. 2004; 122: 330–6
   PubMed Web of Science ®Google Scholar